Your session is about to expire
← Back to Search
This trial tests a new drug, DWN12088, to see if it is safe and effective for treating Idiopathic Pulmonary Fibrosis.
- Idiopathic Pulmonary Fibrosis
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Find a Location
Who is running the clinical trial?
- You have experienced a sudden worsening of your lung condition called IPF within the past 6 months or during the screening period.You have not taken any experimental drugs for IPF in the past 4 weeks before screening.You have been diagnosed with a lung disease called IPF according to certain guidelines from medical societies.
- Group 1: DWN12088 Xmg Tablet (BID)
- Group 2: Placebo 0mg Tablet (BID)
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has DWN12088 been given the green light from the FDA?
"Due to the limited amount of evidence available for DWN12088's efficacy, it was given a safety ranking score of 2. However, there is some research that substantiates its safety."
What are the desired outcomes of this clinical experiment?
"The principal objective of this medical trial, which will be monitored over the course of 24 weeks, is to establish a rate for Forced Vital Capacity (FVC) decrease. Additionally, Quantitative High-Resolution Computed Tomography (HRCT), Time To Progression Of Idiopathic Pulmonary Fibrosis (IPF), and Diffusing Capacity Of Lung For Carbon Monoxide Corrected By Haemoglobin levels will also be tracked as secondary objectives."
Is this investigation accepting new recruits?
"Unfortunately, according to the details posted on clinicaltrials.gov, this particular medical trial is no longer recruiting participants; it was initially published on August 30th 2022 and last updated July 25th 2022. However, fortunately there are currently 410 other studies actively enrolling patients at this time."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
Share this study with friends